ccnd1 polymorphism is associated with early lung cancer and contributes to susceptibility to lung cancer

cyclin D1 overexpression is associated with non-small cell lung cancer

After adjustment for age, sex, and smoking status, the AG genotype was associated with an increased risk for overall lung cancer

Alterations in adenomatous polyposis coli/beta-catenin pathway and cyclin D1 dysregulation may contribute to pathogenesis of pleuropulmonary desmoid tumors and solitary fibrous tumors.

p53 and Ki-67, but not bcl-2, cyclin D1 or HER-2 may have roles in the process of tumor genesis in non-small cell lung carcinoma

CCND1/GAPDH mRNA levels were significantly higher in lung cancer with EGFR mutation than in lung cancer without EGFR mutation

expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.

UBE1L-ISG15 preferentially inhibits cyclin D1 in lung cancer

non-small-cell lung cancer patients with eIF4E(+)/cyclin D1(-) have poorer outcome, those with eIF4E(-)/cyclin D1(+) have a more favorable outcome, and those with eIF4E(+)/cyclin D1(+) have an intermediate outcome (P = .02)

overexpressed cyclin B1, veiling the effect of cyclin D1 or cyclin E, mediated nickel-caused M-phase blockage and cell growth inhibition, which may render pulmonary cells more sensitive to DNA damage and facilitates cancer initiation

Overexpressions of nuclear cyclin D1 is associated with non-small cell lung cancer.

High cyclin D1 is associated with squamous cell carcinoma in non-small cell lung cancer.

CCND1 rs9344 polymorphism together with smoking habit maybe a useful biomarker for lung cancer prediction.

We didn't reveal any important correlations between clinicopathological findings and galectin-3 and cyclin D1 expression and in non small cell lung cancer. We didn't observed also prognostic value of cyclin D1 or galectin-3 expression.

Rsf-1 is overexpressed in non-small cell lung cancers and contributes to malignant cell growth by cyclin D1 and ERK modulation.

Meta-analyses of available data show a significant association between the CCND1 G870A polymorphism and lung cancer risk, and CCND1 G870A polymorphic variant A contributes to increased risk of lung cancer.

A allele of CCND1 G870A polymorphism confers additional lung cancer.

Study assesses the role ofCCND1 genetic variants in fl uencing the genetic susceptibility of non-small cell lung cancer.

GCN5 has a role in potentiating growth of non-small cell lung cancer by promoting E2F1, cyclin D1, and cyclin E1 expression

Results of a meta-analysis suggest that the CCND1 G870A polymorphism might be a low-penetrant risk factor for lung cancer, particularly among Asians and smokers.

Studies suggest that Cyclin D1 (CCND1) G870A polymorphism may be a risk factor for lung cancer.

Aberrant expression of both cyclin D1 and CDC6 by YB-1 over-expression may collaboratively participate in lung carcinogenesis.

PSAT1 expression positively correlates with the levels of phosphorylated cyclin D1 in non-small cell lung cancer.

ZNF322A overexpression transcriptionally dysregulates genes involved in cell growth and motility therefore contributes to lung tumorigenesis and poor prognosis

FOXP3 could enhance lung adenocarcinoma cell proliferation via upregulating the levels of the cell cycle G1/S checkpoint gene CCND1.

Study suggests that cyclin D1 may be an independent prognostic factor for recurrence-free survival in stage II-IIIA adenocarcinoma of lung.

High CCND1 expression is associated with non-small-cell lung cancer.

Increased nuclear CCND1 is a potential unfavorable prognostic factor for lung adenocarcinoma patients, especially those with clinical early stage (stage I+II).

these results demonstrated that miR-146a-5p could suppress the proliferation and cell cycle progression in non-small cell lung cancer cells by inhibiting the expression of CCND1 and CCND2

cyclin D1 is a direct target of transcription factor SOX2 in human lung squamous cell carcinoma cells.

Results identified NKX2-1-binding motifs in the cyclin D1 promoter and indicate that NKX2-1 directly and positively regulates transcription of cyclin D1 in lung adenocarcinoma.

We conclude that EMSY and CCND1 work in collaboration and contribute to the pathogenesis of lung cancer.

transcription factor c-Jun bound to the promoter region of human miR-374a and suppressed miR-374a in A549 and pc-9 cells while inducing it in SPCA-1 and H1975 cells. Increased levels of miR-374a appeared to serve a protective role by targeting CCND1 in early-stage non-small-cell lung cancer.

High CCND1 expression is associated with lung adenocarcinoma.

CCND1 G870A polymorphism may increase the risk of lung cancer in smokers from North India, and it may be associated with the overall survival of small-cell lung cancer patients

Results show that CCND1 expression is regulated by LET7A which directly targets its 3'UTR in A549 lung cancer cells.

USP22 and CCND1 levels correlate in patient lung and colorectal cancer samples and our preclinical studies indicate that targeting USP22 in combination with CDK inhibitors may offer an approach for treating cancer patients whose tumors exhibit elevated CCND1.

set of differentially expressed microRNAs in non-small lung cancer (NSCLC) was identified and the CCND1 gene was determined as the potential prognostic biomarkers for NSCLC.

Cyclin D1 expression is regulated by Hes3 in lung cancer cells.

circ_0007766 can up-regulate the expression of Cyclin D1/Cyclin E1/CDK4, which are the key proteins of cell cycle, and thus promote the malignant proliferation of lung adenocarcinoma

Findings show that CCND1 expression is up-regulated in non-small cell lung cancer (NSCLC) and associated with TCEAL7 under-expression in lung tumors.

MCM10 is highly expressed in lung cancer (LC) clinical specimens and significantly associated with recurrence, pathological stage and worse overall survival. MCM10 knockdown in A549 and H661 cell lines significantly suppressed cell viability, clone formation and induced G1 phase arrest by regulating the expression of CCND1. Results indicated a combined effect of MCM10CCND1 in predicting the prognosis of LC patients.

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer.

Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.

Linc00703 suppresses non-small cell lung cancer progression by modulating CyclinD1/CDK4 expression.

Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.

Cyclin K interacts with beta-catenin to induce Cyclin D1 expression and facilitates tumorigenesis and radioresistance in lung cancer.